Fermentalg (ALGAE.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ALGAE.PA · Stock Price

EUR 0.57+0.10 (+21.18%)

Market Cap: $64.8M

Historical price data

Overview

Fermentalg's mission is to unlock the potential of aquatic microorganisms to create sustainable BioSolutions for nutrition, health, and the environment. The company has evolved from a research start-up into an industrial-scale player, validated by strategic manufacturing alliances with HuvePharma and SUEZ, and key commercial partnerships with Givaudan. Its strategy centers on a dual production technology platform (precision fermentation and photosynthesis) and a deep, proprietary strain library to supply natural ingredients like Omega-3 DHA, antioxidants, and proteins.

NutritionEnvironmental Health

Technology Platform

An integrated biotechnology platform featuring a proprietary library of 2,500+ microalgae strains and dual production systems (precision fermentation in bioreactors and precision photosynthesis) for the scalable, sustainable production of high-value ingredients.

Opportunities

Fermentalg is positioned to capitalize on powerful macro trends: the global shift toward sustainable, plant-based ingredients in nutrition and the demand for natural food colors.

Its recent positive EFSA opinion for Galdieria Blue™ is a significant regulatory catalyst that could accelerate adoption in the large European food and beverage market.

Risk Factors

Key risks include commercialization execution through partners, ongoing regulatory approvals in key markets, intense competition from larger ingredient companies, and the financial challenge of reaching profitability from its current early-revenue stage with a relatively small market capitalization.

Competitive Landscape

Fermentalg competes with established fermentation players like DSM/Firmenich in omega-3s and various natural colorant suppliers. Its differentiated, asset-light platform and strategic partnerships (e.g., with Givaudan for distribution) provide a route to market, but it faces pressure from well-capitalized incumbents and a crowded field of alternative ingredient startups.

More companies in Synthetic Biology →More companies in France →